A Phase 2 interventional study of Psilocybin and Accelerated intermittent theta burst (aiTBS) rTMS treatment in Treatment Resistant Depression, MDD and Major Depressive Disorder, sponsored by University of Texas at Austin. Recruiting at 1 site in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by University of Texas at Austin · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.
Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 6th largest by planned enrollment, is one of 3 that started in 2025, is one of 18 in phase 2, reaches primary completion later than 11 of the 13 other live ones, and was the 13th registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–70
Centre Hospitalier St Anne · Sites in France
Ages 18+
Beersheva Mental Health Center · Sites in Israel
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
University Hospital, Ghent · Sites in Belgium
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 22 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 19 · Phase 3 3
First in 2019; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 30 across the 25 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 25 have an industry lead sponsor. The 10 most frequent:
University of Texas at Austin is the lead sponsor of 328 studies on the registry; 79 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
University of Texas at Austin has 1 study filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
3 of the studies testing psilocybin in Depressive Disorder, Treatment-Resistant that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06731621Centre for Addiction and Mental HealthPsilocybin for Treatment-Resistant Depression in Autism | 2027-01 |
| NCT06518720Centre for Addiction and Mental HealthTreatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | 2027-03 |
| NCT07183748Beersheva Mental Health CenterPsilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.
This will be a phase II 2x2 design (device and dose) clinical trial. 100 participants, ages 22-76, with treatment-resistant MDD will be randomized to treatment with either: a) 25mg of COMP360 (N=50); or b) 1mg of COMP360 (low-dose comparator; N=50) with appropriate psychological preparation, support, and integration sessions with trained therapists. This will then be directly followed by one of two subsequent treatment conditions: i) the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold50,51; or ii) sham iTBS delivered in the same fashion. Individuals will undergo screening, a baseline clinical assessment and neurobiological assessment of functional magnetic resonance imaging (fMRI) and electroencephalographic (EEG) recordings. Individuals will then return on a subsequent day to begin the course of psilocybin therapy. Preparation sessions will occur on the first two out of five days (\~1.5-2 hrs each day), psilocybin dosing will occur on the third day (\~6-8 hours), integration session (\~1 hour) and post-dosing assessments will occur on the fourth day, and a final integration session (\~1 hour) and post-psilocybin clinical and neurobiological assessments will occur on the last of the five days. The following week, the individual will return to the lab to begin the course of active or sham SNT, for 10 hrs. a day (10 min once per 60 min, 50-minute inter-session interval, repeated 10 times daily) for 5 days. This is the protocol now FDA-cleared for treatment of treatment-resistant MDD, known as Stanford Neuromodulation Therapy and commercialized by Magnus Medical (see support letter from Magus Medical). In the third week, the individual will return to complete post-SNT clinical assessments and to complete a post-SNT neurobiological (fMRI and EEG) assessment. Individuals will complete long-term follow-up clinical assessments at 1 month, 2 months, 3 months, 4 months, 6 months, 9 months, and 12 months post-initiation of first treatment (psilocybin administration) to assess durability of clinical response and identify potential points of depression relapse over a sustained period of time.
Aims:
To determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.
To determine if the combination of psilocybin therapy followed by SAINT demonstrates superior efficacy relative to either treatment alone acutely (primary acute endpoint will be \~14 days after the initiation of the treatment sequence) and over time (additional endpoints at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, and 12 months following cessation of the treatment protocol).
To determine the neurobiological changes following the combination treatment (assessment points at baseline, 2 days post-psilocybin, and \~14 days post-psilocybin/2-4 days post cessation of accelerated theta burst), and if the magnitude or nature of such changes are different from those demonstrated in either treatment alone.
Investigate how psychedelic treatment may impact blood biomarkers of inflammation (e.g., inflammatory cytokines) and how select functional genetic polymorphisms may moderate the effect of the psychedelic treatment on subsequent functional brain changes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
25mg of COMP360 with the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) delivered over 10 sessions daily for 5 consecutive days.
Drug: Psilocybin · Device: Accelerated intermittent theta burst (aiTBS) rTMS treatment
25mg of COMP360 with sham iTBS delivered over 10 sessions daily for 5 consecutive days.
Drug: Psilocybin · Device: Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment
1mg of COMP360 with the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) delivered over 10 sessions daily for 5 consecutive days.
Device: Accelerated intermittent theta burst (aiTBS) rTMS treatment · Drug: Low-dose psilocybin
1mg of COMP360 with with sham iTBS delivered over 10 sessions daily for 5 consecutive days.
Drug: Low-dose psilocybin · Device: Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment
A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (COMP360).
Also known as: COMP360
A form of non-invasive brain stimulation that delivers a series of quick magnetic pulses to the scalp and a portion of the brain. It will be targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold.
Also known as: Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), Stanford Neuromodulation Therapy (SNT)
A psychedelic drug found in certain mushrooms. It will be in a low-dose form of the experimental dose as a 1mg capsule of psilocybin (COMP360).
Also known as: low-dose COMP360
The sham version is meant to look and feel like the active SAINT rTMS, but the main difference is that the brain is not being stimulated like the active condition.
Also known as: Sham Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), Sham Stanford Neuromodulation Therapy (SNT)
Montgomery Asberg Depression Rating Scale (MADRS)
A ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Scoring ranging from 0 to 60, with higher scores indicating greater depressive symptomology.
Time frame: 12 months
fMRI task-evoked brain activation
A method used in functional magnetic resonance imaging (fMRI) to observe different areas of the brain or other organs, which are found to be active at any given time.
Time frame: At both 1 week and 2 weeks
fMRI resting state
A method aimed at examining intrinsic networks in the brain while no task is performed (rest) in order to estimate correlations between brain regions.
Time frame: At both 1 week and 2 weeks
EEG functional connectivity change
A method aimed at examining intrinsic networks in the brain to estimate correlations between brain regions.
Time frame: At both 1 week and 2 weeks
Snaith Hamilton Pleasure Scale (SHAPS)
A self-report measure of anhedonia. Scoring range from 0 to 14, with lower scores indicating less anhedonia.
Time frame: 12 months
Quick Inventory of Depressive Symptom Self-Report (QIDS-SR)
A self report measure of depressive symptoms. Scores range from 0 to 48, with lower scores indicating less symptoms of depression.
Time frame: 12 months
World Health Organization Quality of Life Inventory-Brief subscale (WHO-QL-Brief)
A self-report measure of quality of life with four subscales: Physical Health, Psychological Health, Social Relationships, and Environment. Scores for each range from 4-20, with higher scores indicating better quality of life.
Time frame: 12 months
Beck Depression Inventory II (BDI II)
A self-report measure of positive and negative affect. There are scores for Positive Affect and Negative Affect, each of which is scored from 10-50. Higher scores indicate more of that particular type of affect.
Time frame: 12 months
Anxiety Sensitivity Index 3 (ASI-3)
A self-report measure of anxiety sensitivity. Scores range from 0 to 72, with lower scores indicating less anxiety sensitivity.
Time frame: 12 months
Beck Anxiety Inventory (BAI)
A self report measure of anxiety symptoms. Scores range from 0 to 63, with lower scores indicating less anxiety.
Time frame: 12 months
Mood and Anxiety Symptom Questionnaire 30 item Anhedonic Depression subscale (MASQ-30)
A subscale measure of anhedonic depressive symptoms. Scores range from 10-50, with lower scores indicating less anhedonic depression.
Time frame: 12 months
Mood and Anxiety Symptom Questionnaire 30 item Anxious Arousal subscale (MASQ-30)
A subscale measure of anxious arousal symptoms. Scores range from 10-50, with lower scores indicating less anxious arousal.
Time frame: 12 months
Physicians Health Questionnaire 9 (PHQ-9)
A self-report screener of major depression. Scores range from 0 to 27, with lower scores indicating fewer symptoms of depression.
Time frame: 12 months
Generalized Anxiety Disorder 7 (GAD-7)
A self-report screener of generalized anxiety disorder. Scores range from 0 to 21, with lower scores indicating less symptoms of generalized anxiety.
Time frame: 12 months
Columbia-Suicide Severity Rating Scale (C-SSRS)
Clinician-administered measure of suicidal ideation. Scores range from 0 to 25, with higher scores indicating more severe suicidal ideation.
Time frame: 12 months
Anger Attacks Questionnaire (AAQ)
Self-report measure of anger outbursts. Scores range from 5-25, with higher scores indicating more severe expressions of anger.
Time frame: 12 months
Brief Psychiatric Rating Scale (BPRS)
A tool clinicians or researchers use to measure psychiatric symptoms such as anxiety, depression, and psychoses. Scores range from 18 to 126, with lower scores indicating less severe psychiatric symptoms a score of 18 meaning no symptoms present.
Time frame: 2 weeks
Sheehan Disability Scale (SDS)
Self-report screener that measures impairment in functioning and generates 4 scores: a work disability score, a social life disability score, a family life disability score and a total score. To get a total score add up the 3 individual scores (work: social life: family life). The maximum possible score is 30, meaning more severe impairment from experienced disability.
Time frame: 12 months
Positive and Negative Affect Scale Short Form (PANAS-SF)
Self-Report scale that consists of different words that describe feelings and emotions to measure positive and negative affect. Scores are divided into two categories: 1) can range from 10-50 with higher scores representing higher levels of positive affect and 2) can range from 10-50 with lower scores representing lower levels of negative affect.
Time frame: 12 months
Acceptance and Action Questionnaire II (AAQ II)
Self-report measure that tracks how individuals are applying flexibility skills to their daily lives. 7 item scale with scores ranging from 7-49,with higher scores indicating higher psychological inflexibility, experiential avoidance, and more potential for psychological stress.
Time frame: 12 months
NEO Five Factor Inventory (NEO-FFI)
Self-report measure that assesses subjects for five domains of normal personality: neuroticism, extraversion, conscientiousness, agreeableness, and openness. Each domain is a 12-item scale with scores ranging from 12-60 where the combined scores create a personality profile.
Time frame: 12 months
Emotion Regulation Questionnaire (ERQ)
A 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Assesses cognitive reappraisal (6 items) and expressive suppression (4 items) on a 7-point Likert-type response scale, with higher scores on each scale indicate greater use of the corresponding emotional regulation strategy. Min 10 - max 70.
Time frame: 12 months
UCLA Loneliness Scale 3 (UCLA-LS-3)
Clinician administered scale that comprises 3 questions that measure three dimensions of loneliness: relational connectedness, social connectedness, and self-perceived isolation. Each item is rated on a 3-point scale for a range of 3-9, with higher scores meaning more intense feelings of the 3 dimensions of loneliness.
Time frame: 12 months
Freiberg Mindfulness Inventory (FMI)
Self-report questionnaire for measuring mindfulness. A 14-item scale with scores 14-56 with higher scores meaning a higher degree of mindfulness.
Time frame: 12 months
Discontinuation Emergent Signs and Symptoms Scale
Self-report measure of 43-items that assess changes in symptomology when starting a new treatment. This measures does not correlate scores to an outcome but is used to assess the development of a new symptom or the worsening of an already existing one.
Time frame: 1 week
Plan to share: No — If participants chose to, they can be included in the Department of Psychiatry's Registry (Protocol 2020-04-0046). Participants may elect to be part of this registry, but this is not required as part of the participation in the current study. No other plans for sharing data outside of a research related inquiry for research purposes is expected. The registry informed consent will be provided to the participant if interested and consent will be obtained per procedures outlined in the registry protocol. De-identified data may be shared with future researchers for scientific purposes. If our lab shares biospecimens with future researchers, it will only be de-identified data. In this case, it will be shared in the form of an aggregated database with no PHI or PII included.
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2029, 59 months after the start.
Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 59 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Depressive Disorder, Treatment-Resistant →
University of Texas at Austin →